V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330005079 | 330002437 | null | 7.7 | Palliative (P) | 2018-06-29 | 2018-07-06 | Epirubicin | N | N | 330021370 | CARBOPLATIN + PEMETREXED |
| 330005080 | 330002438 | 1.8 | 77.4 | Palliative (P) | 2017-12-13 | 2018-01-03 | CNS Low Grade Glioma Vinblastine | N | N | 330021377 | FLUDARABINE |
| 330005081 | 330002439 | 1.7 | null | Palliative (P) | 2014-05-05 | 2014-05-06 | IMATINIB | N | null | 330021381 | DOXORUBICIN + IFOSFAMIDE |
| 330005082 | 330002439 | 1.58 | 14.3 | Disease modification (D) | 2016-11-17 | 2016-12-02 | EDP | N | N | 330021381 | BLEOMYCIN + CARBOPLATIN + ETOPOSIDE |
| 330005083 | 330002440 | 0 | 54.4 | null | 2017-01-03 | 2017-01-06 | Cisplatin + Docetaxel | N | null | 330021391 | DOXORUBICIN + OLARATUMAB |
| 330005086 | 330007341 | null | null | null | null | 2015-02-14 | Pazopanib | null | null | 330021428 | CISPLATIN + DOX + ETOPOSIDE |
| 330005087 | 330007341 | null | null | Neo-adjuvant (N) | 2015-10-19 | 2015-10-21 | Trabectedin | N | N | 330021428 | VIDE |
| 330005088 | 330007341 | 1.62 | 79 | Neo-adjuvant (N) | 2013-02-24 | 2013-02-24 | NB BEACON Temozolomide Bevacizumab | 02 | N | 330021428 | CYTARABINE |
| 330005089 | 330002442 | 0 | 35 | Curative (C) | 2014-02-10 | 2014-02-11 | Cisplatin + Fluorouracil + RT 5day | 2 | N | 330021437 | SUNITINIB |
| 330005090 | 330002442 | 1.87 | 77 | Palliative (P) | 2015-01-18 | 2015-01-19 | Hydroxycarbamide | Y | Y | 330021437 | MITOTANE |
| 330005091 | 330002443 | 1.71 | 60 | Curative (C) | 2013-08-02 | 2013-08-02 | Cisplatin + Fluorouracil + RT 5day | 02 | N | 330021449 | MITOTANE |
| 330005098 | 330002444 | 1.66 | 98 | Adjuvant (A) | 2016-06-21 | 2016-07-04 | Etoposide + Ifosfamide (3 days) | N | N | 330021497 | BLEOMYCIN + CARBOPLATIN + ETOPOSIDE |
| 330005099 | 330002444 | 1.83 | 75.9 | Curative (C) | 2014-08-16 | 2014-08-16 | FLAG + Idarubicin | 02 | N | 330021497 | VINBLASTINE |
| 330005100 | 330002444 | 1.7 | 107.9 | Disease modification (D) | 2015-01-22 | 2015-01-28 | BLEOMYCIN | N | N | 330021497 | FLUDARABINE |
| 330005101 | 330002444 | 1.8 | null | Palliative (P) | 2018-03-02 | 2018-03-03 | Bendamustine + prednisolone | N | N | 330021497 | PACLITAXEL |
| 330005102 | 330002445 | 0 | 75.9 | Palliative (P) | 2016-06-29 | 2016-07-05 | Enzalutamide | N | N | 330021531 | CHOP |
| 330005103 | 330002446 | null | null | null | 2013-07-24 | 2013-08-08 | RUXOLITINIB | null | N | 330021535 | CISPLATIN + PEMETREXED |
| 330005104 | 330002446 | 1.74 | 58.9 | Curative (C) | 2017-03-05 | 2017-03-10 | BLEOMYCIN + CISPLATIN + VINCRISTINE | 02 | N | 330021535 | VIDE |
| 330005108 | 330002448 | 1.54 | null | Palliative (P) | 2016-09-15 | 2016-09-24 | FLUOROURACIL + MITOMYCIN | N | N | 330021567 | CHLORAMBUCIL |
| 330005109 | 330002448 | 1.83 | 136 | Curative (C) | 2017-07-23 | 2017-07-23 | AML 18 TRIAL | 02 | N | 330021567 | DASATINIB |
| 330005110 | 330002449 | 1.16 | 77 | Palliative (P) | 2016-02-08 | 2016-02-22 | CHOP R - 21 days | 2 | N | 330021571 | CHLORAMBUCIL |
| 330005111 | 330002450 | 1.58 | 67.1 | null | null | 2014-06-10 | FLUOROURACIL + MITOMYCIN | null | null | 330021574 | AML17 TRIAL |
| 330005112 | 330002450 | null | 81.9 | Curative (C) | null | 2017-06-11 | Hydroxycarbamide | N | null | 330021574 | CYTARABINE |
| 330005113 | 330002450 | 0 | 76.9 | Curative (C) | 2014-09-03 | 2014-09-06 | GEM-P | Y | N | 330021574 | DOCETAXEL + GEMCITABINE |
| 330005114 | 330002451 | 1.74 | 92 | Neo-adjuvant (N) | 2016-07-07 | 2016-07-21 | Capecitabine | N | N | 330021585 | AML17 TRIAL |
| 330005115 | 330002451 | 1.65 | 63 | Curative (C) | 2014-05-25 | 2014-08-21 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | N | N | 330021585 | EDP |
| 330005117 | 330002453 | 1.87 | 102.7 | Palliative (P) | 2013-10-31 | 2013-11-19 | AML16 DA 3+8 | N | N | 330021589 | VIDE |
| 330005118 | 330002453 | 1.8 | 90.3 | Palliative (P) | 2017-05-02 | 2017-05-02 | Mitotane 3 - 3.5g | N | N | 330021589 | IPILIMUMAB + NIVOLUMAB |
| 330005119 | 330002454 | 1.7 | 56 | null | 2015-11-01 | 2015-11-10 | Capecitabine + Cisplatin | 2 | N | 330021596 | AML17 TRIAL |
| 330005120 | 330002455 | 1.61 | 12.8 | Palliative (P) | 2017-07-26 | 2017-07-27 | CARBOPLATIN + RT | 02 | N | 330021598 | CAPE + CARBOPLATIN + CETUXIMAB |
| 330005121 | 330002456 | 1.83 | 89 | Adjuvant (A) | 2013-02-27 | 2013-03-01 | Aldesleukin | 2 | N | 330021602 | CISPLATIN + DOCETAXEL |
| 330005122 | 330002456 | null | 77.95 | Disease modification (D) | 2016-05-02 | 2016-05-24 | Azacitidine | N | N | 330021602 | VIDE |
| 330005123 | 330002457 | 0 | 99 | null | 2013-10-15 | 2013-10-15 | CARBOPLATIN + DOCETAXEL + FLUOROURACIL | 02 | N | 330021618 | DOXORUBICIN + IFOSFAMIDE |
| 330005124 | 330002457 | 1.69 | 84.7 | Disease modification (D) | 2018-07-25 | 2018-08-23 | EDP + MITOTANE | 2 | N | 330021618 | CISPLATIN + FLUOROURACIL + RT |
| 330005125 | 330002457 | 1.87 | 72.3 | Curative (C) | 2017-10-16 | 2017-11-02 | CAPECITABINE + OXALIPLATIN | 02 | N | 330021618 | CAPECITABINE + CARBOPLATIN |
| 330005126 | 330002458 | 1.48 | 71.2 | Curative (C) | 2017-10-17 | 2017-10-18 | Bendamustine +/- Prednisolone | 2 | N | 330021634 | METHOTREXATE INTRATHECAL |
| 330005127 | 330002458 | 1.6 | null | Disease modification (D) | 2017-01-20 | 2017-01-20 | CHOP - 14 days | null | null | 330021634 | CISPLATIN + DOCETAXEL |
| 330005128 | 330002458 | null | 56.2 | null | 2013-03-20 | 2013-03-20 | FLUOROURACIL + MITOMYCIN + RT | N | N | 330021634 | PILOT TRIAL |
| 330005130 | 330002460 | 1.81 | 63 | Curative (C) | 2015-04-03 | 2015-04-03 | Gemcitabine weekly | 02 | null | 330021651 | NIVOLUMAB |
| 330005131 | 330002460 | 1.61 | 73 | Neo-adjuvant (N) | null | 2015-01-16 | CARBOPLATIN + RT | N | N | 330021651 | DABRAFENIB |
| 330005132 | 330002461 | null | 74.35 | Disease modification (D) | 2012-12-24 | 2013-01-09 | R Chlorambucil | N | N | 330021655 | RUXOLITINIB |
| 330005133 | 330002461 | 1.55 | 123 | Curative (C) | 2017-01-25 | 2017-02-01 | CARBOPLATIN + RT | N | N | 330021655 | FLUOROURACIL + MITOMYCIN + RT |
| 330005134 | 330002462 | null | 23.2 | Curative (C) | 2014-04-24 | 2014-04-24 | PEMBROLIZUMAB | N | N | 330021667 | CARBOPLATIN + RT |
| 330005135 | 330002463 | 1.71 | 80 | Curative (C) | null | 2015-12-19 | IBRUTINIB | N | N | 330021669 | DOXORUBICIN + IFOSFAMIDE |
| 330005136 | 330002464 | 1.8 | 37.7 | Palliative (P) | 2013-10-30 | 2013-10-31 | Docetaxel + Gemcitabine with GCSF | 2 | N | 330021673 | BEP |
| 330005137 | 330002464 | 1.8 | null | Palliative (P) | null | 2015-07-16 | EW Rel rEECur Irinotecan/Temozolomide | N | N | 330021673 | ECX |
| 330005138 | 330002464 | 1.7 | 74 | Palliative (P) | 2017-12-22 | 2017-12-22 | EDP + MITOTANE | 02 | N | 330021673 | MITOTANE |
| 330005139 | 330011457 | 1.79 | 65.1 | Adjuvant (A) | 2013-11-18 | 2013-11-18 | Bortezomib + CYCLOPHOSPHAMIDE | Y | N | 330021687 | CISPLATIN + DOX + ETOPOSIDE |
| 330005140 | 330011457 | null | 127.4 | Curative (C) | 2016-05-14 | 2016-05-14 | Cisplatin + Pemetrexed | N | N | 330021687 | HYDROXYCARBAMIDE |
| 330005141 | 330002465 | 1.64 | 56.2 | Palliative (P) | 2016-01-28 | 2016-02-08 | Doxorubicin + Ifosfamide | N | N | 330021690 | ETOPOSIDE + IFOSFAMIDE |